Genmab A/S (GEN.CO) Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL  
3/19/2012 9:55:39 AM

COPENHAGEN, Denmark, March 19, 2012 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today the submission of a protocol amendment for the ofatumumab Phase III head-to-head study in diffuse large B-cell lymphoma (DLBCL) to regulatory authorities. According to the amended protocol all patients recruited in the study which investigates ofatumumab plus chemotherapy versus rituximab plus chemotherapy in relapsed or refractory DLBCL, will receive the same chemotherapy regimen (DHAP). This change will revise underlying timing assumptions in the study and could bring forward the primary endpoint analysis to early 2014.